Plain-English translation of NCT06552598 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer treatment called KD01, which uses a specially engineered virus to help your immune system fight gynecologic cancers like cervical and endometrial cancer. The treatment is injected directly into the tumor. Researchers want to see if this medication is safe, well-tolerated, and effective—especially for younger women who hope to preserve their ability to have children in the future.
Standard treatments for early-stage gynecologic cancers often require surgery or chemotherapy that can affect fertility. This trial explores whether the medication might offer an alternative that could preserve reproductive health while effectively treating cancer, and to understand how it works to kill cancer cells.
You likely qualify if…
You likely don't qualify if…
You would receive direct injections of the treatment (KD01) into your tumor under medical supervision. The trial has two phases: Phase I includes patients whose cancer has not responded to standard treatments, while Phase II focuses on younger women with early-stage disease who want fertility preservation. You will have regular clinic visits for physical exams, blood tests, imaging scans, and immune function studies to monitor how the treatment is working and watch for side effects. The exact schedule and duration will be explained during your screening visit.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China